These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

446 related items for PubMed ID: 28890196

  • 21. Comparisons in the Health and Economic Assessments of Using Quadrivalent Versus Trivalent Influenza Vaccines: A Systematic Literature Review.
    Warmath CR, Ortega-Sanchez IR, Duca LM, Porter RM, Usher MG, Bresee JS, Lafond KE, Davis WW.
    Value Health; 2023 May; 26(5):768-779. PubMed ID: 36436790
    [Abstract] [Full Text] [Related]

  • 22. Safety and immunogenicity of a quadrivalent intradermal influenza vaccine in adults.
    Gorse GJ, Falsey AR, Ozol-Godfrey A, Landolfi V, Tsang PH.
    Vaccine; 2015 Feb 25; 33(9):1151-9. PubMed ID: 25613721
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Enhanced passive safety surveillance of three marketed influenza vaccines in the UK and the Republic of Ireland during the 2017/18 season.
    Gandhi-Banga S, Chabanon AL, Eymin C, Caroe T, Butler K, Moureau A.
    Hum Vaccin Immunother; 2019 Feb 25; 15(9):2154-2158. PubMed ID: 30897026
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Economic evaluation of high-dose inactivated influenza vaccine in adults aged ≥65 years: A systematic literature review.
    Colrat F, Thommes E, Largeron N, Alvarez FP.
    Vaccine; 2021 Mar 15; 39 Suppl 1():A42-A50. PubMed ID: 33518466
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Safety and immunogenicity of a quadrivalent influenza vaccine in adults 65 y of age and older.
    Greenberg DP, Robertson CA, Talbot HK, Decker MD.
    Hum Vaccin Immunother; 2017 Sep 02; 13(9):2058-2064. PubMed ID: 28700265
    [Abstract] [Full Text] [Related]

  • 29. Clinical trial to assess immunogenicity of high-dose, adjuvanted, and recombinant influenza vaccines against cell-grown A(H3N2) viruses in adults 65 to 74 years, 2017-2018.
    Belongia EA, Levine MZ, Olaiya O, Gross FL, King JP, Flannery B, McLean HQ.
    Vaccine; 2020 Mar 30; 38(15):3121-3128. PubMed ID: 32145994
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Influenza vaccines effectiveness 2013-14 through 2015-16, a test-negative study in children.
    Valdin HL, Bégué RE.
    Vaccine; 2017 Jul 24; 35(33):4088-4093. PubMed ID: 28669621
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Immunogenicity and safety of high-dose quadrivalent influenza vaccine in Japanese adults ≥65 years of age: a randomized controlled clinical trial.
    Sanchez L, Matsuoka O, Inoue S, Inoue T, Meng Y, Nakama T, Kato K, Pandey A, Chang LJ.
    Hum Vaccin Immunother; 2020 Apr 02; 16(4):858-866. PubMed ID: 31634025
    [Abstract] [Full Text] [Related]

  • 36. Cost-effectiveness analysis of quadrivalent versus trivalent influenza vaccine in Taiwan: A lifetime multi-cohort model.
    Yang MC, Tan EC, Su JJ.
    Hum Vaccin Immunother; 2017 Jan 02; 13(1):81-89. PubMed ID: 27624648
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.